サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1349442

フラグメント創薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Fragment Based Drug Discovery Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
フラグメント創薬市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年07月31日
発行: Transparency Market Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

フラグメント創薬市場- レポートの範囲

世界のフラグメント創薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、2023年を基準年、2031年を予測年とし、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、フラグメント創薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 7億9,540万米ドル
2031年の市場価値 21億米ドル
CAGR11.5%

このレポートは、世界のフラグメント創薬市場の競合情勢を詳しく掘り下げています。世界のフラグメント創薬市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のフラグメント創薬市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • 技術の進歩
  • 主要な業界イベント
  • 地域/世界ごとの規制シナリオ
  • 関与する主な調査機関
  • COVID-19感染症パンデミックによる業界への影響（バリューチェーンと短期・中期・長期的な影響）

第6章 世界市場の分析と予測：コンポーネント別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：コンポーネント別、2017-2031
    • フラグメントスクリーニング
      • 生物物理学的手法
        • NMR分光法
        • 示差走査蛍光分析（DSF）アッセイ
        • 蛍光偏光
        • 等温滴定熱量測定
        • X線結晶構造解析
        • 表面プラズモン共鳴（SPR）
        • 二重層干渉法
        • 質量分析（MS）
        • キャピラリー電気泳動
        • 弱アフィニティークロマトグラフィー（WAC-HPLC-UV/MS）
        • その他のアッセイ（生化学）
      • 非生物物理学的手法
    • フラグメントの最適化
  • 市場魅力度分析：コンポーネント別

第7章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：用途別、2017-2031
    • 腫瘍学
    • 中枢神経系（CNS）障害
    • 感染症
    • 心血管疾患
    • 代謝障害
    • 炎症と自己免疫疾患
  • 市場魅力分析：用途別

第8章 世界市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：エンドユーザー別、2017-2031
    • 学術・調査機関
    • 製薬およびバイオテクノロジー企業
    • 受託調査機関（CRO）
  • 市場魅力度分析：エンドユーザー別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米の世界市場の分析と予測

第11章 欧州の世界市場の分析と予測

第12章 アジア太平洋地域の世界市場の分析と予測

第13章 ラテンアメリカの世界市場の分析と予測

第14章 中東およびアフリカの世界市場の分析と予測

第15章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別、2021年
  • 企業プロファイル
    • Alveus Pharmaceuticals Pvt. Ltd.
    • Astex Pharmaceuticals
    • Charles River Laboratories International, Inc.
    • Beactica AB
    • Emerald BioStructures, Inc.
    • Crown Bioscience, Inc.
    • Evotec AG
    • Proteros Fragments GmbH
    • Kinetic Discovery Limited
    • Sprint Bioscience
    • Sygnature Discovery
    • Structure Based Design, Inc.
図表

List of Tables

  • Table 01: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 03: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 04: Global Fragment Based Drug Discovery Market Size (US$ Million) Forecast, by Region, 2017-2031
  • Table 05: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country, 2017-2031
  • Table 06: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 07: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 08: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 09: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 11: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 12 Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 15: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 19: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 20: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Component, 2017-2031
  • Table 23: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01. Global Fragment Based Drug Discovery Market Size (US$ Million) and Distribution, by Region, 2022 and 2031
  • Figure 02: Global Fragment Based Drug Discovery Market Value (US$ Million) Forecast, 2017-2031
  • Figure 03: Global Fragment Based Drug Discovery Market Value Share, by Component (2022)
  • Figure 04: Global Fragment Based Drug Discovery Market Value Share, by Application (2022)
  • Figure 05: Global Fragment Based Drug Discovery Market Value Share, by End-user (2022)
  • Figure 06: Global Fragment Based Drug Discovery Market Value Share, by Component, 2022 and 2031
  • Figure 07: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Fragment Screening, 2017-2031
  • Figure 08: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Fragment Optimization, 2017-2031
  • Figure 09: Global Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 10: Global Fragment Based Drug Discovery Market Value Share, by Application, 2022 and 2031
  • Figure 11: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Oncology, 2017-2031
  • Figure 12: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Central Nervous System (CNS) Disorders, 2017-2031
  • Figure 13: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Infectious Diseases, 2017-2031
  • Figure 19: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Cardiovascular Diseases, 2017-2031
  • Figure 14: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Metabolic Disorders, 2017-2031
  • Figure 15: Global Fragment Based Drug Discovery Market Revenue (US$ Million) Forecast and Y-o-Y Growth (%) Projection, by Inflammation & Autoimmune Diseases, 2017-2031
  • Figure 16: Global Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 17: Global Fragment Based Drug Discovery Market Value Share, by End-user, 2022 and 2031
  • Figure 18: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Academic & Research Institutions, 2017-2031
  • Figure 19: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 20: Global Fragment Based Drug Discovery Market Revenue (US$ Million) and Y-o-Y Growth (%) Forecast, by Contract Research Organizations (CROs), 2017-2031
  • Figure 21: Global Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 22: Global Fragment Based Drug Discovery Market Value Share, by Region, 2022 and 2031
  • Figure 23: Global Fragment Based Drug Discovery Market Attractiveness, by Region, 2017-2031
  • Figure 24: North America Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%) 2017-2031
  • Figure 25: North America Fragment Based Drug Discovery Market Value Share, by Country, 2022 and 2031
  • Figure 26: North America Fragment Based Drug Discovery Market Attractiveness, by Country, 2017-2031
  • Figure 27: North America Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 28: North America Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 29: North America Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 30: Europe Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 31: Europe Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 32: Europe Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 33: Europe Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 34: Europe Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 35: Europe Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 36: Asia Pacific Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 37: Asia Pacific Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 38: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 39: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 40: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 41: Asia Pacific Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 42: Latin America Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 43: Latin America Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 44: Latin America Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 45: Latin America Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 46: Latin America Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 47: Latin America Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
  • Figure 48: Middle East & Africa Fragment Based Drug Discovery Market Value (US$ Million) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 49: Middle East & Africa Fragment Based Drug Discovery Market Value Share, by Country/Sub-region, 2022 and 2031
  • Figure 50: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Country/Sub-region, 2017-2031
  • Figure 51: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Component, 2017-2031
  • Figure 52: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by Application, 2017-2031
  • Figure 53: Middle East & Africa Fragment Based Drug Discovery Market Attractiveness, by End-user, 2017-2031
目次
Product Code: TMRGL4741

Fragment Based Drug Discovery Market - Scope of Report

TMR's report on the global fragment based drug discovery market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global fragment based drug discovery market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fragment based drug discovery market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fragment based drug discovery market.

Market Snapshot
Market Value in 2023US$ 795.4 Mn
Market Value in 2031US$ 2.1 Bn
CAGR11.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fragment based drug discovery market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fragment based drug discovery market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fragment based drug discovery market.

The report delves into the competitive landscape of the global fragment based drug discovery market. Key players operating in the global fragment based drug discovery market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fragment based drug discovery market profiled in this report.

Key Questions Answered in Global Fragment Based Drug Discovery Market Report:

  • What is the sales/revenue generated by fragment based drug discovery across all regions during the forecast period?
  • What are the opportunities in the global fragment based drug discovery market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fragment Based Drug Discovery Market - Research Objectives and Research Approach

The comprehensive report on the global fragment based drug discovery market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fragment based drug discovery market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fragment based drug discovery market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fragment Based Drug Discovery Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fragment Based Drug Discovery Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Key Industry Events
  • 5.3. Regulatory Scenario by Region/Globally
  • 5.4. Major Research Institutes Involved
  • 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Component

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Component, 2017-2031
    • 6.3.1. Fragment Screening
      • 6.3.1.1. Biophysical Techniques
        • 6.3.1.1.1. NMR Spectroscopy
        • 6.3.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 6.3.1.1.3. Fluorescence Polarization
        • 6.3.1.1.4. Isothermal Titration Calorimetry
        • 6.3.1.1.5. X-ray Crystallography
        • 6.3.1.1.6. Surface Plasmon Resonance (SPR)
        • 6.3.1.1.7. Bilayer Interferometry
        • 6.3.1.1.8. Mass Spectrometry (MS)
        • 6.3.1.1.9. Capillary Electrophoresis
        • 6.3.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 6.3.1.1.11. Other Assays (Biochemical)
      • 6.3.1.2. Non-biophysical Techniques
    • 6.3.2. Fragment Optimization
  • 6.4. Market Attractiveness Analysis, by Component

7. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Oncology
    • 7.3.2. Central Nervous System (CNS) Disorders
    • 7.3.3. Infectious Diseases
    • 7.3.4. Cardiovascular Diseases
    • 7.3.5. Metabolic Disorders
    • 7.3.6. Inflammation & Autoimmune Diseases
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Fragment Based Drug Discovery Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Academic & Research Institutions
    • 8.3.2. Pharmaceutical & Biotechnology Companies
    • 8.3.3. Contract Research Organizations (CROs)
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Fragment Based Drug Discovery Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Component, 2017-2031
    • 10.2.1. Fragment Screening
      • 10.2.1.1. Biophysical Techniques
        • 10.2.1.1.1. NMR Spectroscopy
        • 10.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 10.2.1.1.3. Fluorescence Polarization
        • 10.2.1.1.4. Isothermal Titration Calorimetry
        • 10.2.1.1.5. X-ray Crystallography
        • 10.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 10.2.1.1.7. Bilayer Interferometry
        • 10.2.1.1.8. Mass Spectrometry (MS)
        • 10.2.1.1.9. Capillary Electrophoresis
        • 10.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 10.2.1.1.11. Other Assays (Biochemical)
      • 10.2.1.2. Non-biophysical Techniques
    • 10.2.2. Fragment Optimization
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Oncology
    • 10.3.2. Central Nervous System (CNS) Disorders
    • 10.3.3. Infectious Diseases
    • 10.3.4. Cardiovascular Diseases
    • 10.3.5. Metabolic Disorders
    • 10.3.6. Inflammation & Autoimmune Diseases
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Academic & Research Institutions
    • 10.4.2. Pharmaceutical & Biotechnology Companies
    • 10.4.3. Contract Research Organizations (CROs)
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Component
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Component, 2017-2031
    • 11.2.1. Fragment Screening
      • 11.2.1.1. Biophysical Techniques
        • 11.2.1.1.1. NMR Spectroscopy
        • 11.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 11.2.1.1.3. Fluorescence Polarization
        • 11.2.1.1.4. Isothermal Titration Calorimetry
        • 11.2.1.1.5. X-ray Crystallography
        • 11.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 11.2.1.1.7. Bilayer Interferometry
        • 11.2.1.1.8. Mass Spectrometry (MS)
        • 11.2.1.1.9. Capillary Electrophoresis
        • 11.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 11.2.1.1.11. Other Assays (Biochemical)
      • 11.2.1.2. Non-biophysical Techniques
    • 11.2.2. Fragment Optimization
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Oncology
    • 11.3.2. Central Nervous System (CNS) Disorders
    • 11.3.3. Infectious Diseases
    • 11.3.4. Cardiovascular Diseases
    • 11.3.5. Metabolic Disorders
    • 11.3.6. Inflammation & Autoimmune Diseases
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Academic & Research Institutions
    • 11.4.2. Pharmaceutical & Biotechnology Companies
    • 11.4.3. Contract Research Organizations (CROs)
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Component
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Component, 2017-2031
    • 12.2.1. Fragment Screening
      • 12.2.1.1. Biophysical Techniques
        • 12.2.1.1.1. NMR Spectroscopy
        • 12.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 12.2.1.1.3. Fluorescence Polarization
        • 12.2.1.1.4. Isothermal Titration Calorimetry
        • 12.2.1.1.5. X-ray Crystallography
        • 12.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 12.2.1.1.7. Bilayer Interferometry
        • 12.2.1.1.8. Mass Spectrometry (MS)
        • 12.2.1.1.9. Capillary Electrophoresis
        • 12.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 12.2.1.1.11. Other Assays (Biochemical)
      • 12.2.1.2. Non-biophysical Techniques
    • 12.2.2. Fragment Optimization
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Oncology
    • 12.3.2. Central Nervous System (CNS) Disorders
    • 12.3.3. Infectious Diseases
    • 12.3.4. Cardiovascular Diseases
    • 12.3.5. Metabolic Disorders
    • 12.3.6. Inflammation & Autoimmune Diseases
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Academic & Research Institutions
    • 12.4.2. Pharmaceutical & Biotechnology Companies
    • 12.4.3. Contract Research Organizations (CROs)
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Component
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Component, 2017-2031
    • 13.2.1. Fragment Screening
      • 13.2.1.1. Biophysical Techniques
        • 13.2.1.1.1. NMR Spectroscopy
        • 13.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 13.2.1.1.3. Fluorescence Polarization
        • 13.2.1.1.4. Isothermal Titration Calorimetry
        • 13.2.1.1.5. X-ray Crystallography
        • 13.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 13.2.1.1.7. Bilayer Interferometry
        • 13.2.1.1.8. Mass Spectrometry (MS)
        • 13.2.1.1.9. Capillary Electrophoresis
        • 13.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 13.2.1.1.11. Other Assays (Biochemical)
      • 13.2.1.2. Non-biophysical Techniques
    • 13.2.2. Fragment Optimization
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Oncology
    • 13.3.2. Central Nervous System (CNS) Disorders
    • 13.3.3. Infectious Diseases
    • 13.3.4. Cardiovascular Diseases
    • 13.3.5. Metabolic Disorders
    • 13.3.6. Inflammation & Autoimmune Diseases
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Academic & Research Institutions
    • 13.4.2. Pharmaceutical & Biotechnology Companies
    • 13.4.3. Contract Research Organizations (CROs)
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Component
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Global Fragment Based Drug Discovery Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Component, 2017-2031
    • 14.2.1. Fragment Screening
      • 14.2.1.1. Biophysical Techniques
        • 14.2.1.1.1. NMR Spectroscopy
        • 14.2.1.1.2. Differential Scanning Fluorimetry (DSF) Assay
        • 14.2.1.1.3. Fluorescence Polarization
        • 14.2.1.1.4. Isothermal Titration Calorimetry
        • 14.2.1.1.5. X-ray Crystallography
        • 14.2.1.1.6. Surface Plasmon Resonance (SPR)
        • 14.2.1.1.7. Bilayer Interferometry
        • 14.2.1.1.8. Mass Spectrometry (MS)
        • 14.2.1.1.9. Capillary Electrophoresis
        • 14.2.1.1.10. Weak Affinity Chromatography (WAC - HPLC-UV/MS)
        • 14.2.1.1.11. Other Assays (Biochemical)
      • 14.2.1.2. Non-biophysical Techniques
    • 14.2.2. Fragment Optimization
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Oncology
    • 14.3.2. Central Nervous System (CNS) Disorders
    • 14.3.3. Infectious Diseases
    • 14.3.4. Cardiovascular Diseases
    • 14.3.5. Metabolic Disorders
    • 14.3.6. Inflammation & Autoimmune Diseases
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Academic & Research Institutions
    • 14.4.2. Pharmaceutical & Biotechnology Companies
    • 14.4.3. Contract Research Organizations (CROs)
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Component
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Alveus Pharmaceuticals Pvt. Ltd.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Astex Pharmaceuticals
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Charles River Laboratories International, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Beactica AB
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Emerald BioStructures, Inc.
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Crown Bioscience, Inc.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Evotec AG
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Proteros Fragments GmbH
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Kinetic Discovery Limited
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Sprint Bioscience
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Sygnature Discovery
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Structure Based Design, Inc.
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview